Introduction: The persistence of the COVID-19 pandemic, which has become a global public health problem, means that the implementation of effective and affordable diagnostic strategies is essential, particularly in developing countries, to contain the disease. Rapid, reliable and inexpensive molecular or antigenic tests enable early detection of cases and rapid clinical management. The method based on reverse transcription-polymerase chain reaction (RT-PCR) is the benchmark for diagnosing SARS-CoV-2 infections. However, this method requires highly qualified human resources, complex equipment, consumables and reagents that are usually expensive and imported from developed countries. Given these technical and financial constraints and the limited capacity of molecular platforms in developing countries, point-of-care can be considered a very good alternative. The aim of this study was to evaluate the performance of the ID NOWTM COVID-19 test for the detection of SARS-COV-2 from nasopharyngeal swab samples collected in tubes containing viral transport medium compared with RT-PCR. Method: The evaluation was carried out on 59 travellers from whom a nasopharyngeal swab was taken in 3 ml of viral transport medium (VTM). A swab from the ID-NOW kit was dipped into each sample and then deposited in the sample recipient in order to assess the performance of the ID-NOW test compared with RT-PCR. Results: In our study, we found a sensitivity of 92.6% (23/25) and a specificity of 100%. However, 2 false negatives were found with samples that had CT values of 36. No cross-contamination between samples was observed in this study. Conclusion: Our data showed that the ID NOWTM COVID-19 test would be an excellent tool for screening suspected cases in clinical departments.
| Published in | International Journal of Immunology (Volume 11, Issue 2) |
| DOI | 10.11648/j.iji.20231102.11 |
| Page(s) | 13-16 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
SARS-CoV-2, COVID-19, ID-NOW, RT-PCR
| [1] | Mohan BS and V Nambiar. (2020). COVID-19: An Insight into SARS-CoV-2 Pandemic Originated at Wuhan City in Hubei Province of China. J Infect Dis Epidemiol 6: 146. DOI: 10.23937/2474-3658/1510146. |
| [2] | Ibrahima Diouf, Abdoulaye Bousso, Ibrahima Sonko. (2020). Gestion de la pandémie COVID-19 au Sénégal. Médecine de Catastrophe-Urgences Collectives. Volume 4, Issue 3, Pages 217-222. Doi.org/10.1016/j.pxur.2020.08.009. |
| [3] | Hantz S. (2020) Diagnostic biologique de l’infection à Sars-CoV-2: stratégies et interprétation des résultats [Biological diagnosis of Sars-CoV-2 infection: strategies and interpretation of results]. Rev Francoph Lab. Nov; 2020(526): 48-56. French. doi: 10.1016/S1773-035X (20)30313-0. |
| [4] | Burdino E, Cerutti F, Milia MG, Allice T, Gregori G, Aprà F, De Iaco F, Aluffi E, Micca G, Ghisetti V. (2022). Fast and reliable real life data on COVID-19 triaging with ID NOW. J Clin Virol Plus. Feb; 2(1): 100065. doi: 10.1016/j.jcvp.100065. Epub 2022 Jan 15. PMID: 35262036; PMCID: PMC8760098. |
| [5] | K. Uhteg, J. Jarrett, M. Richards, C. Howard, E. Morehead, M. Geahr, L. Gluck, A. Hanlon, B. Ellis, H. Kaur, P. Simner, K. C. Carroll, H. H. Mostafa. (2020). Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays, J. Clin. Virol. 127, doi: 10.1016/j.jcv.2020.104384. |
| [6] | Mitchell SL, George KS. (2020). Evaluation of the COVID19 ID NOW EUA assay. J Clin Virol. Jul; 128: 104429. Doi: 10.1016/j.jcv.2020.104429. |
| [7] | ID NOW COVID-19 Technical Brief-April 2020, Sample Type Labelling Update, Abbott Diagnostics Scarborough, Inc, 2020 EUA2000047. |
| [8] | Abbott, ID NOWTM Covid-19 Product Insert, U. S. Food Drug Adm. (2020). |
| [9] | Mbow Moustapha, Diallo Ibrahima, Diouf Mamadou, Cissé Marouba et al. (2022) Evaluation of the LumiraDx SARS-CoV-2 antigen assay for large-scale population testing in Senegal. International Journal of Clinical Virology. vol. 6, no. 1, pp. 001–006, Jan. 2022, doi: 10.29328/journal.ijcv.1001041. |
| [10] | Lephart PR, Bachman MA, LeBar W, McClellan S, Barron K, Schroeder L, Newton DW. (2020) Comparative study of four SARS-CoV-2 nucleic acid amplification test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type. bioRxiv. doi: 10.1101/2020.06.04.135616. |
| [11] | Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M, Gopal R. (2020). Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill. Aug; 25(32): 2001483. doi: 10.2807/1560-7917.ES.2020.25.32.2001483. Erratum in: Euro Surveill. 2021 Feb; 26(7): PMID: 32794447; PMCID: PMC7427302. |
| [12] | Sarkar B, Sinha R, Sarkar K. (2020). Initial viral load of a COVID-19-infected case indicated by its cycle threshold value of polymerase chain reaction could be used as a predictor of its transmissibility-An experience from Gujarat, India. Indian J. Community Med 45, 278–282. |
| [13] | Rao SN, Manissero D, Steele VR, Pareja J. (2020). A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. Infect. Dis. Ther, 9, 573–586. |
| [14] | Sepulveda JL, Abdulbaki R, Sands Z, Codoy M, Mendoza S, Isaacson N, Kochar O, Keiser J, Haile-Mariam T, Meltzer AC, Mores CN, Sepulveda AR. (2021). Performance of the Abbott ID NOW rapid SARS-CoV-2 amplification assay in relation to nasopharyngeal viral RNA loads. J Clin Virol. 2021 Jul; 140: 104843. doi: 10.1016/j.jcv.2021.104843. |
APA Style
Ndao Malick, Diagne Babacar, Diagne Rokhaya, Niane Moustapha, Ka Roughyatou. (2023). Comparative Evaluation of the ID NOWTM Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers. International Journal of Immunology, 11(2), 13-16. https://doi.org/10.11648/j.iji.20231102.11
ACS Style
Ndao Malick; Diagne Babacar; Diagne Rokhaya; Niane Moustapha; Ka Roughyatou. Comparative Evaluation of the ID NOWTM Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers. Int. J. Immunol. 2023, 11(2), 13-16. doi: 10.11648/j.iji.20231102.11
AMA Style
Ndao Malick, Diagne Babacar, Diagne Rokhaya, Niane Moustapha, Ka Roughyatou. Comparative Evaluation of the ID NOWTM Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers. Int J Immunol. 2023;11(2):13-16. doi: 10.11648/j.iji.20231102.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.iji.20231102.11,
author = {Ndao Malick and Diagne Babacar and Diagne Rokhaya and Niane Moustapha and Ka Roughyatou},
title = {Comparative Evaluation of the ID NOWTM Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers},
journal = {International Journal of Immunology},
volume = {11},
number = {2},
pages = {13-16},
doi = {10.11648/j.iji.20231102.11},
url = {https://doi.org/10.11648/j.iji.20231102.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20231102.11},
abstract = {Introduction: The persistence of the COVID-19 pandemic, which has become a global public health problem, means that the implementation of effective and affordable diagnostic strategies is essential, particularly in developing countries, to contain the disease. Rapid, reliable and inexpensive molecular or antigenic tests enable early detection of cases and rapid clinical management. The method based on reverse transcription-polymerase chain reaction (RT-PCR) is the benchmark for diagnosing SARS-CoV-2 infections. However, this method requires highly qualified human resources, complex equipment, consumables and reagents that are usually expensive and imported from developed countries. Given these technical and financial constraints and the limited capacity of molecular platforms in developing countries, point-of-care can be considered a very good alternative. The aim of this study was to evaluate the performance of the ID NOWTM COVID-19 test for the detection of SARS-COV-2 from nasopharyngeal swab samples collected in tubes containing viral transport medium compared with RT-PCR. Method: The evaluation was carried out on 59 travellers from whom a nasopharyngeal swab was taken in 3 ml of viral transport medium (VTM). A swab from the ID-NOW kit was dipped into each sample and then deposited in the sample recipient in order to assess the performance of the ID-NOW test compared with RT-PCR. Results: In our study, we found a sensitivity of 92.6% (23/25) and a specificity of 100%. However, 2 false negatives were found with samples that had CT values of 36. No cross-contamination between samples was observed in this study. Conclusion: Our data showed that the ID NOWTM COVID-19 test would be an excellent tool for screening suspected cases in clinical departments.},
year = {2023}
}
TY - JOUR T1 - Comparative Evaluation of the ID NOWTM Test (Abott) and RT-PCR for the Detection of the SARS-CoV-2 Genome in Travellers AU - Ndao Malick AU - Diagne Babacar AU - Diagne Rokhaya AU - Niane Moustapha AU - Ka Roughyatou Y1 - 2023/09/14 PY - 2023 N1 - https://doi.org/10.11648/j.iji.20231102.11 DO - 10.11648/j.iji.20231102.11 T2 - International Journal of Immunology JF - International Journal of Immunology JO - International Journal of Immunology SP - 13 EP - 16 PB - Science Publishing Group SN - 2329-1753 UR - https://doi.org/10.11648/j.iji.20231102.11 AB - Introduction: The persistence of the COVID-19 pandemic, which has become a global public health problem, means that the implementation of effective and affordable diagnostic strategies is essential, particularly in developing countries, to contain the disease. Rapid, reliable and inexpensive molecular or antigenic tests enable early detection of cases and rapid clinical management. The method based on reverse transcription-polymerase chain reaction (RT-PCR) is the benchmark for diagnosing SARS-CoV-2 infections. However, this method requires highly qualified human resources, complex equipment, consumables and reagents that are usually expensive and imported from developed countries. Given these technical and financial constraints and the limited capacity of molecular platforms in developing countries, point-of-care can be considered a very good alternative. The aim of this study was to evaluate the performance of the ID NOWTM COVID-19 test for the detection of SARS-COV-2 from nasopharyngeal swab samples collected in tubes containing viral transport medium compared with RT-PCR. Method: The evaluation was carried out on 59 travellers from whom a nasopharyngeal swab was taken in 3 ml of viral transport medium (VTM). A swab from the ID-NOW kit was dipped into each sample and then deposited in the sample recipient in order to assess the performance of the ID-NOW test compared with RT-PCR. Results: In our study, we found a sensitivity of 92.6% (23/25) and a specificity of 100%. However, 2 false negatives were found with samples that had CT values of 36. No cross-contamination between samples was observed in this study. Conclusion: Our data showed that the ID NOWTM COVID-19 test would be an excellent tool for screening suspected cases in clinical departments. VL - 11 IS - 2 ER -
Information
Email: